Mirna Expression Profiles Identify Drivers in Colorectal and Pancreatic Cancers

Piepoli, Ada; Tavano, Francesca; Copetti, Massimiliano; Mazza, Tommaso; Palumbo, Orazio; Panza, Anna; Mola, Fabio F. di; Pazienza, Valerio; Mazzoccoli, Gianluigi; Biscaglia, Giuseppe; Gentile, Annamaria; Mastrodonato, Nicola; Carella, Massimo; Pellegrini, Fabio; Sebastiano, Pierluigi di; Andriulli, Angelo

doi:10.1371/journal.pone.0033663

Cited by 130 publications

(96 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The study by Mar-Aguilar et al confirmed the upregulation of miR-382 in the serum of patients with breast cancer; a sensitivity of 94.40% and a specificity of 90.00% was found for the diagnosis of breast cancer (24). A study by Li et al showed that miR-382-5p expression was significantly downregulated in patients with ductal carcinoma in situ (25), while miR-1246 was demonstrated to exhibit high expression in colorectal cancer (26), esophageal squamous cell carcinoma (27), cervical carcinoma (28), hepatocellular carcinoma (29) and other cancers. The expression profiles of miRNAs in the serum and tissues are different.…”

Section: A B C Dmentioning

confidence: 92%

Serum expression levels of microRNA-382-3p, −598-3p, −1246 and −184 in breast cancer patients

Zhu

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. The purpose of the present study was to investigate the serum levels of microRNA (miRNA/miR)-382-3p, -598-3p, -1246 and -184 in breast cancer patients and to assess their feasibility as biomarkers for breast cancer screening. Serum samples were obtained from 100 breast cancer patients and 40 age-matched healthy control subjects in Taizhou Central Hospital (Taizhou, Zhejiang, China) between January 2013 and September 2014. The serum expression levels of miR-382-3p, -598-3p, -1246 and -184 were determined by stem-loop reverse transcription-quantitative polymerase chain reaction. Receiver operating characteristic curves were drawn to evaluate the sensitivity and specificity of the serum miRNA expression levels for the screening of breast cancer. miR-382-3p and -1246 were significantly upregulated in the serum of the breast cancer patients, while miR-598-3p and -184 were significantly downregulated. The sensitivity and specificity to detect breast cancer were as follows: miR-382-3p, 52.0 and 92.5%; miR-598-3p, 95.0 and 85.0%; miR-1246, 93.0 and 75.0%; and miR-184, 87.5 and 71.0%, respectively. The expression levels of the four serum miRNAs were not correlated with the patients' clinical stage. In summary, miR-382-3p, -598-3p, -1246 and -184 are all involved in the development of breast cancer, and are promising biomarkers for breast cancer detection. IntroductionBreast cancer has become the most common cancer in women in China, accounting for 12.2% of all newly diagnosed breast cancers and 9.6% of all mortalities from breast cancer worldwide (1). Early detection of breast cancer is the key to successful treatment and patient survival. Mammographies, magnetic resonance imaging and ultrasound are being used for the screening of breast cancer, but these techniques have limitations such as low sensitivity and specificity (2). Finding effective biomarkers is vital for the screening of breast cancer.MicroRNAs (miRNAs/miRs) are a group of small non-coding RNAs (3), which can bind to the 3' untranslated region (UTR), the 5' UTR (4) or the coding region (5) of target mRNA. miRNAs play important roles in the negative regulation of gene expression in a post-transcriptional manner, and are involved in a number of signal transduction pathways, including cell proliferation, differentiation, apoptosis, immune response and angiogenesis (6). Previous studies have revealed the abnormal expression of miRNAs in the development and progression of breast cancer (7), and miRNAs are closely linked with tumor-associated signal transduction pathways (8). In our previous study, 10 miRNAs that were significantly differentially expressed were found by the second generation of high-throughput sequencing technology, Illumina Hiseq2500 (9). In the present study, 4 miRNAs, miR-382-3p, -598-3p, -1246 and -184, were further investigated. The purpose of this study was to investigate the serum levels of these miRNAs in breast cancer patients and to assess their feasibility as biomarkers for breast cancer screening. Materials and methods Subje...

show abstract

Section: A B C Dmentioning

confidence: 92%

Serum expression levels of microRNA-382-3p, −598-3p, −1246 and −184 in breast cancer patients

Zhu

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Gene expression profiling has already demonstrated its effectiveness at subtyping various cancers, however miRNA profiles are equally discriminatory and can even be more informative, as changes in their expression can provide insights into the myriad of gene permutations observed in various cancer subtypes: links have indeed been made between misregulated miRNAs and the target genes that are affected, thus unraveling some of the unique gene networks involved [117]. miRNA profiles may identify cancer-specific signatures distinguishing between normal and cancerous tissue [118][119][120][121], but they can also discriminate different subtypes of a particular cancer [119,122,123].…”

Section: Mirnas As Prognostic Biomarkersmentioning

confidence: 99%

microRNA: New Players in Metastatic Process

Triulzi¹,

Iorio²,

Tagliabue³

et al. 2013

Oncogene and Cancer - From Bench to Clinic

View full text Add to dashboard Cite

“…A total of 25% of patients with colorectal cancer have a genetic history, which is associated with familial adenomatous polyposis and hereditary non-polyposis colorectal cancer (7). Results of molecular pathology and colorectal cancer expression profile chip screening have demonstrated that multiple genes serve regulatory roles in the processes of colorectal cancer development (8). In order to identify possible gene target therapies and individualized treatments, various studies have focused on genes associated with the pathogenesis of colorectal cancer and their mechanisms.…”

Section: Introductionmentioning

confidence: 99%

Expression and clinical significance of Sirt1 in colorectal cancer

Jiang

Pan

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. The objective of the present study was to examine the expression of Silent information regulator 1 (Sirt1) in colorectal cancer and peritumoral normal mucosa tissue, and therefore analyze the role and molecular mechanism of Sirt1 in the pathogenesis of colorectal cancer. Colorectal cancer tissue specimens were employed as the experimental group, and adjacent normal mucosa tissues >5 cm from tumor lesions were used as the control group. The expression of Sirt1 was detected by the immunohistochemical streptavidin peroxidase detection method in paraffin-embedded sections, whilst Sirt1 protein expression was examined by western blot analysis in the fresh tissues. Sirt1 protein was primarily expressed in the nuclei of the tumor cells, and positive staining was brownish-yellow in color. The relative expression quantities of Sirt1 in the peritumoral normal rectal mucosa and rectal carcinoma were 1.15 and 2.62, and the differences between the two groups were statistically significant (P<0.05). The expression level of Sirt1 in colorectal carcinoma was significantly associated with the depth of tumor invasion, differentiation and tumor size (P<0.05). Sirt1 expression was also found to be associated with tumor tissue type, lymph node metastasis, Duke's stage and patient age. These characteristics combined may therefore be used as markers for the early diagnosis of colorectal cancer pathogenesis. IntroductionColorectal cancer occurs in the colorectal mucosa and colonic glands and is one of the most common types of malignant tumor of the digestive system (1,2). The worldwide incidence and mortality rates of colorectal cancer increased significantly between 2009 and 2013; in 2013, a total of 142,820 new cases were diagnosed and 50,830 mortalities occurred as a result of colorectal cancer (3). Thus, this malignancy presents a serious threat to human health (1,2). Clinical and pathological data of patients with colorectal cancer in China have demonstrated the following pathogenic characteristics: The number of patients in cities is higher than that in the countryside, indicating a clear urbanization trend; and patients <30 years of age account for >10% of the total number of patients, demonstrating a clear trend towards older age (4). Surgical resection is currently the main method used for the treatment of colorectal cancer. However, as significant symptoms are often not present in the early stages of the disease, patients are frequently diagnosed in the later stages; by this time, the optimal period for surgery has passed. Furthermore, metastasis or recurrence occurs in a large number of patients following surgical resection, affecting the prognosis of the patients. Therefore, the five-year survival rate is low (64%), posing a serious threat to patient health (5,6).The occurrence and pathogenesis of colorectal cancer is a complex, multistep process, regulated by a number of different genes (1). A total of 25% of patients with colorectal cancer have a genetic history, which is associated with familial adenomatous pol...

show abstract

Mirna Expression Profiles Identify Drivers in Colorectal and Pancreatic Cancers

Cited by 130 publications

References 27 publications

Serum expression levels of microRNA-382-3p, −598-3p, −1246 and −184 in breast cancer patients

Serum expression levels of microRNA-382-3p, −598-3p, −1246 and −184 in breast cancer patients

microRNA: New Players in Metastatic Process

Expression and clinical significance of Sirt1 in colorectal cancer

Contact Info

Product

Resources

About